2 Recession-Resistant Dividend Stocks to Buy Now

CVS yields 3.4% and has grown its dividend 56.5% over the past decade; Gilead has a ~2.3% forward yield and has increased payouts 90.7% over ten years. CVS’s diversified mix (pharmacy, pharmacy services, primary care, insurance) and its decision to scale back unprofitable Medicare Advantage exposure aim to restore margins after recent cost headwinds, while Gilead’s durable HIV franchise (Biktarvy, Descovy), mixed Veklury COVID revenues, and an expanding oncology pipeline underpin recession resilience and potential future sales upside.

Analysis

CVS: the most actionable lever is not store count but the evolving mix between pharmacy dispensing, PBM gross-to-net dynamics, and the shrinking Medicare Advantage book. Exiting unprofitable MA segments should reduce near-term revenue scale but can materially re-rate margins as reserve volatility and medical loss ratio unpredictability decline; the second-order effect is less captive pharmacy foot traffic, which will pressure retail/non-pharmacy adjacency sales and shift incremental profit responsibility onto PBM and clinic channels. Watch CMS rate guidance and PBM contracting cadence over the next 3-9 months — margin inflection there will be the cleanest signal of earnings durability.

Gilead: the balance sheet can absorb a volatile Veklury cycle while funding buybacks and oncology tuck-ins, making capital allocation the key optionality rather than short-term sales prints. The market underprices how a successful mid-stage oncology readout (12–24 months) could re-rate multiples because oncology revenues carry higher pricing leverage and recurring hospital channel economics versus episodic antivirals. Offset risks include price negotiations on chronic therapies and potential HIV generic erosion over a multi-year horizon; those are slow-moving but could compress multiples if compounded by macro-driven payer reforms.

Cross-cutting: both names benefit from defensive demand but face different regulatory vectors — CVS from CMS/insurance dynamics, Gilead from FDA/HTA outcomes and patent cliffs. A portfolio that leans into CVS for near-term margin stabilization and Gilead for asymmetric biotech upside should size catalyst risk (CMS announcements, FDA readouts) explicitly and use option structures to finance asymmetric payoffs. Monitor unemployment and outpatient visit trends as 1–4 quarter leading indicators for pharmacy volumes and clinic utilization.

Key Decisions for Investors

• Long CVS equity with covered-call overlay: buy shares size = 2–3% portfolio; sell 12-month OTM calls to fund ~50–75% of expected dividend+carry. Timeframe: 9–15 months. R/R: target total return 15–25% if margins stabilize; downside -20–25% if CMS/MA deterioration re-emerges. Close if CMS issues adverse MA guidance or PBM gross-to-net widens beyond guidance.
• Long GILD bullish LEAP call spread: buy 2028 LEAP calls and sell higher-strike 2028 calls (e.g., buy 2028 $X C / sell 2028 $Y C) sized to risk 1–2% portfolio. Timeframe: 18–36 months to encompass oncology catalysts. R/R: asymmetric upside 2–4x if a late-stage oncology asset succeeds; max loss limited to premium paid if trials disappoint or Veklury volatility continues.
• Pair trade (defensive tilt): long CVS / short NFLX sized dollar-neutral, horizon 6–12 months. Rationale: expresses rotation into healthcare defensives vs discretionary growth; expect outperformance if macro softens or ad-spend slows. Risk: growth re-acceleration would flip performance — cap position size and use stop-loss at 8–10% adverse move.
• Risk hedge: buy protection (puts) on CVS for 6–9 months keyed to CMS announcement windows and buy protection on GILD around nearest major oncology readout to cap single-event downside. Size hedges to limit loss on core positions to predetermined thresholds (e.g., total drawdown cap 7–10% per name).